ALMKS Fundamental Analysis - MAKING SCIENCE GROUP SA

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to ALMKS. ALMKS was compared to 62 industry peers in the Media industry. Both the profitability and financial health of ALMKS have multiple concerns. ALMKS is valued quite expensive, but it does show an excellent growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALMKS has reported negative net income.

In the past year ALMKS had a positive cash flow from operations.

ALMKS had negative earnings in 4 of the past 5 years.

Of the past 5 years ALMKS 4 years had a positive operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -1.00%, ALMKS is doing worse than 66.13% of the companies in the same industry.

Looking at the Return On Equity, with a value of -6.68%, ALMKS is doing worse than 66.13% of the companies in the same industry.

The Return On Invested Capital of ALMKS (7.61%) is better than 70.97% of its industry peers.

		Industry Rank	Sector Rank
ROA	-1%
ROE	-6.68%
ROIC	7.61%

ROA(3y)-2.48%

ROA(5y)-1.44%

ROE(3y)-22.79%

ROE(5y)-9.81%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ALMKS has a Operating Margin of 1.87%. This is comparable to the rest of the industry: ALMKS outperforms 40.32% of its industry peers.

ALMKS's Operating Margin has declined in the last couple of years.

With a Gross Margin value of 20.49%, ALMKS is not doing good in the industry: 80.65% of the companies in the same industry are doing better.

In the last couple of years the Gross Margin of ALMKS has declined.

		Industry Rank	Sector Rank
OM	1.87%
PM (TTM)	N/A
GM	20.49%

OM growth 3YN/A

OM growth 5Y-6.38%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-11.38%

GM growth 5Y-5.28%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALMKS has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.

ALMKS has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, ALMKS has more shares outstanding

Compared to 1 year ago, ALMKS has an improved debt to assets ratio.

2.2 Solvency

ALMKS has an Altman-Z score of 1.75. This is a bad value and indicates that ALMKS is not financially healthy and even has some risk of bankruptcy.

ALMKS's Altman-Z score of 1.75 is in line compared to the rest of the industry. ALMKS outperforms 59.68% of its industry peers.

ALMKS has a debt to FCF ratio of 1126.96. This is a negative value and a sign of low solvency as ALMKS would need 1126.96 years to pay back of all of its debts.

ALMKS has a Debt to FCF ratio of 1126.96. This is comparable to the rest of the industry: ALMKS outperforms 40.32% of its industry peers.

A Debt/Equity ratio of 0.47 indicates that ALMKS is not too dependend on debt financing.

Looking at the Debt to Equity ratio, with a value of 0.47, ALMKS is in the better half of the industry, outperforming 61.29% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.47
Debt/FCF	1126.96
Altman-Z	1.75

ROIC/WACC1.11

WACC6.88%

2.3 Liquidity

A Current Ratio of 0.75 indicates that ALMKS may have some problems paying its short term obligations.

The Current ratio of ALMKS (0.75) is worse than 75.81% of its industry peers.

ALMKS has a Quick Ratio of 0.75. This is a bad value and indicates that ALMKS is not financially healthy enough and could expect problems in meeting its short term obligations.

ALMKS has a Quick ratio of 0.73. This is in the lower half of the industry: ALMKS underperforms 69.35% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.75
Quick Ratio	0.73

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 63.02% over the past year.

Looking at the last year, ALMKS shows a quite strong growth in Revenue. The Revenue has grown by 16.03% in the last year.

ALMKS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 51.21% yearly.

EPS 1Y (TTM)63.02%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-319.11%

Revenue 1Y (TTM)16.03%

Revenue growth 3Y35.32%

Revenue growth 5Y51.21%

Sales Q2Q%21.07%

3.2 Future

ALMKS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.70% yearly.

The Revenue is expected to grow by 22.10% on average over the next years. This is a very strong growth

EPS Next Y30.3%

EPS Next 2Y33.71%

EPS Next 3Y29.7%

EPS Next 5YN/A

Revenue Next Year33.94%

Revenue Next 2Y25.99%

Revenue Next 3Y22.1%

Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALMKS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

ALMKS is valuated rather expensively with a Price/Forward Earnings ratio of 20.41.

ALMKS's Price/Forward Earnings ratio is in line with the industry average.

When comparing the Price/Forward Earnings ratio of ALMKS to the average of the S&P500 Index (22.88), we can say ALMKS is valued inline with the index average.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	20.41

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ALMKS is valued a bit more expensive than the industry average as 64.52% of the companies are valued more cheaply.

The rest of the industry has a similar Price/Free Cash Flow ratio as ALMKS.

		Industry Rank	Sector Rank
P/FCF	1601.02
EV/EBITDA	9.68

4.3 Compensation for Growth

ALMKS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

ALMKS's earnings are expected to grow with 29.70% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y33.71%

EPS Next 3Y29.7%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ALMKS does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MAKING SCIENCE GROUP SA

EPA:ALMKS (9/18/2025, 7:00:00 PM)

8.95

0 (0%)

Chartmill FA Rating

GICS SectorCommunication Services

GICS IndustryGroupMedia & Entertainment

GICS IndustryMedia

Earnings (Last)07-31 2025-07-31

Earnings (Next)N/A N/A

Inst Owners3.56%

Inst Owner ChangeN/A

Ins Owners63.56%

Ins Owner ChangeN/A

Market Cap80.37M

AnalystsN/A

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)-36.76%

EPS NY rev (3m)-36.76%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)7.94%

Revenue NY rev (3m)7.94%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	20.41
P/S	0.29
P/FCF	1601.02
P/OCF	246.61
P/B	3.12
P/tB	N/A
EV/EBITDA	9.68

EPS(TTM)-0.19

EYN/A

EPS(NY)0.44

Fwd EY4.9%

FCF(TTM)0.01

FCFY0.06%

OCF(TTM)0.04

OCFY0.41%

SpS30.46

BVpS2.87

TBVpS-4.49

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-1%
ROE	-6.68%
ROCE	10.35%
ROIC	7.61%
ROICexc	13.76%
ROICexgc	N/A
OM	1.87%
PM (TTM)	N/A
GM	20.49%
FCFM	0.02%

ROA(3y)-2.48%

ROA(5y)-1.44%

ROE(3y)-22.79%

ROE(5y)-9.81%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5Y-6.38%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-11.38%

GM growth 5Y-5.28%

F-Score6

Asset Turnover1.58

Health

		Industry Rank	Sector Rank
Debt/Equity	0.47
Debt/FCF	1126.96
Debt/EBITDA	1.05
Cap/Depr	4.23%
Cap/Sales	0.1%
Interest Coverage	1.14
Cash Conversion	2.8%
Profit Quality	N/A
Current Ratio	0.75
Quick Ratio	0.73
Altman-Z	1.75

F-Score6

WACC6.88%

ROIC/WACC1.11

Cap/Depr(3y)13.72%

Cap/Depr(5y)311.76%

Cap/Sales(3y)0.4%

Cap/Sales(5y)7.85%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)63.02%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-319.11%

EPS Next Y30.3%

EPS Next 2Y33.71%

EPS Next 3Y29.7%

EPS Next 5YN/A

Revenue 1Y (TTM)16.03%

Revenue growth 3Y35.32%

Revenue growth 5Y51.21%

Sales Q2Q%21.07%

Revenue Next Year33.94%

Revenue Next 2Y25.99%

Revenue Next 3Y22.1%

Revenue Next 5YN/A

EBIT growth 1Y279.3%

EBIT growth 3YN/A

EBIT growth 5Y41.57%

EBIT Next Year207.02%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y103.36%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y177.63%

OCF growth 3Y-64.38%

OCF growth 5YN/A

MAKING SCIENCE GROUP SA (ALMKS.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens